The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis

Phase

2/3

Condition

Arthritis And Arthritic Pain

Rheumatoid Arthritis

Joint Injuries

Treatment

N/A

Clinical Study ID

NCT03173040

Niubang Pill

Ages 18-80
All Genders

Study Summary

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that results in the destruction of joints, connective tissues, muscle, tendons and fibrous tissue. Effective therapy to manage RA still does not exit at present. Jia Wei Niu Bang Zi pill (NBZP) consists of Chinese herbals which has been widely used in the treatment of RA patients in China for hundreds of years to relieve pain and prevent the affected joints pejorative. However, there is no systematic trials to prove the effect of NBZP for management of RA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Adults with rheumatoid arthritis (score more then 5 of ACR (American College OfRheumatology) /EULAR (European League Against Rheumatism), 2009 )
moderate-to-severe disease activity (Disease Activity Score for 28-joint counts (DAS28) of more than 3.2
an onset of symptoms within 12 months before enrollment, no prior exposure to morethan 10mg oral glucocorticoids or biologic agents
paid employment or unpaid but measurable work (e.g. caring for a family and home)

Exclusion

Exclusion Criteria:

combined with other disease such as adjuvant arthritis, lupus arthritis,osteoarthritis and et al.
abnormal liver and my kidney function
pregnancy or have a plan of pregnancy,breast feeding women
severe chronic or acute disease interfering with therapy attendance
alcohol or substance abuse

Study Design

July 01, 2018

December 31, 2018

Study Description

A multicenter, randomized, double-blind, placebo-controlled clinical trials will be conducted to determine whether the NBZP could make an effect of pain relief and joints protection. 120 patients suffering from active RA will be enrolled and treated with NBZP or placebo for 3 months. The primary outcome measures are the rate of American College of Rheumatology (ACR) 50, changes of the Disease Activity Score (DAS) 28 from the baseline to 3 months and the van der Heijde modified Sharp score would be measured from the baseline to 12 months. The second outcome measures are the change rate of ACR20, ACR70, Health Assessment Questionnaire - Disability Index, change score of Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, Patient Global Assessment of Arthritis and the Athens Insomnia Scale (AIS) from the baseline to 2 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months' follow-up.

Connect with a study center

Longhua Hospital
Shanghai, Shanghai
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.